Alamar Biosciences (Nasdaq: ALMR) posts 99% Q1 2026 revenue growth
Rhea-AI Filing Summary
Alamar Biosciences, Inc. reported first quarter 2026 results showing rapid growth but continuing losses. Total revenue reached $26.0 million, up 99% from $13.1 million a year earlier, driven by strong instrument, consumable, and services demand.
Instrument revenue rose to $7.4 million, consumables to $14.0 million, and services and other to $4.7 million. Gross margin improved to 56% from 49% on higher volumes and a mix shift toward consumables. Operating expenses increased to $26.8 million, leading to an operating loss of $12.3 million.
Net loss widened to $21.3 million, including an $8.6 million loss on remeasurement of convertible notes. Cash, cash equivalents and restricted cash totaled $69.5 million as of March 31, 2026. After quarter end, Alamar completed its initial public offering, raising $197.8 million of net proceeds to strengthen its balance sheet.
Positive
- Revenue nearly doubled: Q1 2026 revenue reached $26.0 million, a 99% year-over-year increase from $13.1 million, with strength across instruments, consumables, and services.
- Improving profitability profile: Gross margin expanded to 56% from 49%, helped by higher consumables volumes, better pricing, and favorable product mix.
- Significant capital infusion: The April 2026 initial public offering generated $197.8 million of net proceeds, materially strengthening liquidity beyond the $69.5 million cash, cash equivalents and restricted cash at March 31, 2026.
Negative
- Losses widened: Net loss increased to $21.3 million from $7.7 million a year earlier, including an $8.6 million loss on remeasurement of convertible notes, and operating loss rose to $12.3 million.
Insights
Alamar pairs near‑doubling revenue with a much stronger balance sheet but remains loss‑making.
Alamar Biosciences delivered Q1 2026 revenue of $26.0M, up 99% year over year, with growth across instruments, consumables, and services. Gross margin expanded to 56% from 49%, benefiting from scale, higher pricing, and a richer consumables mix.
Operating expenses climbed to $26.8M, up 79%, reflecting heavier R&D, commercial, and professional spending. That produced an operating loss of $12.3M and a net loss of $21.3M, including an $8.6M loss on convertible note remeasurement, underscoring the company’s investment phase.
A key development was the initial public offering completed in April 2026, which generated $197.8M in net proceeds and materially extends liquidity beyond the $69.5M cash, cash equivalents and restricted cash at March 31, 2026. Management plans to provide full‑year 2026 revenue guidance with the Q2 2026 results, which will clarify the expected growth trajectory.
8-K Event Classification
Key Figures
Key Terms
Precision Proteomics financial
Gross margin financial
Convertible notes financial
Stock-based compensation financial
Initial public offering financial
Operating expenses financial
Earnings Snapshot
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02 Results of Operations and Financial Condition.
On May 8, 2026, Alamar Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
All of the information furnished in this Item 2.02 and Exhibit 99.1 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
Exhibit number |
|
Description |
|
|
|
99.1 |
|
Press Release dated May 8, 2026 |
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Alamar Biosciences, Inc. |
|
|
|
|
Date: May 8, 2026 |
By: |
/s/ Justin McAnear |
|
|
Justin McAnear |
|
|
Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) |
Exhibit 99.1
Alamar Biosciences Reports First Quarter 2026 Financial Results
FREMONT, Calif.--(GLOBE NEWSWIRE)—Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today reported financial results for the quarter ended March 31, 2026.
Recent Highlights
"We began 2026 with a record quarter, nearly doubling revenue year over year as our NULISA platform gained rapid global traction among leading academic research and biopharma customers," said Yuling Luo, PhD, founder, CEO, and chair of Alamar Biosciences. "With our balance sheet significantly strengthened by the proceeds of our recent IPO, we are well-positioned to accelerate adoption of our Precision Proteomics platform and establish a new gold standard in protein detection and analysis."
First Quarter 2026 Financial Results
Revenue was $26.0 million for the first quarter of 2026, a 99% increase from $13.1 million for the corresponding prior-year period. Instrument revenue grew 78% to $7.4 million, from $4.1 million for the corresponding prior-year period, driven primarily by an increase in instrument placements. Consumable revenue grew 178% to $14.0 million, from $5.0 million for the corresponding prior-year period, driven primarily by pull-through tied to the larger instrument installed base as well as by a slight increase in the average selling price of our consumables. Services and other revenue grew 20% to $4.7 million, from $3.9 million for the corresponding prior-year period.
Gross margin was 56% for the first quarter of 2026, as compared to 49% for the corresponding prior-year period. The increase in gross margin was primarily driven by manufacturing efficiencies realized through larger consumables production volumes, higher average selling prices across both instruments and consumables, and by a favorable shift in product mix toward higher-margin consumables.
Operating expenses were $26.8 million for the first quarter of 2026, a 79% increase from $14.9 million for the corresponding prior-year period. The year-over-year increase in operating expenses was primarily related to increased personnel costs, increased costs related to expansion of our product offerings, and increased professional costs for legal and accounting services.
Operating loss was $12.3 million for the first quarter of 2026, as compared to an operating loss of $8.6 million for the corresponding prior-year period. This includes $1.5 million of stock-based compensation for the first quarter of 2026, as compared to $0.6 million for the first quarter of 2025.
Net loss was $21.3 million for the first quarter of 2026, including a loss of $8.6 million related to the remeasurement of convertible notes, and higher than the $7.7 million net loss in the corresponding prior-year period.
Cash, cash equivalents, and restricted cash were $69.5 million as of March 31, 2026.
Recent Developments
In April, after quarter end, Alamar Biosciences completed its initial public offering, raising $197.8 million of net proceeds, after deducting underwriter commissions, discounts and other expenses incurred by the company.
The company intends to provide full-year 2026 revenue guidance in conjunction with its second quarter 2026 earnings release in August 2026.
About Alamar Biosciences, Inc.
Alamar is a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Leveraging our proprietary NULISA™ technology and the ARGO™ HT System, our platform is designed to detect protein biomarkers at extremely low concentrations in blood with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation. We refer to this combination of features as “Precision Proteomics,” and believe it fills a critical gap in the field of advanced proteomics, helping researchers unlock the full spectrum of protein biomarkers across disease states.
Forward Looking Statements
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "intends," "may," "plans," "possible," "potential," "seeks," "will" and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding Alamar Biosciences’ future plans and prospects, its ability to accelerate adoption of its platform and establish a new gold standard in protein detection and analysis, anticipated timing and content regarding full-year 2026 guidance, and Alamar Biosciences’ ability to grow its business. Any forward-looking statements in this press release are based on Alamar Biosciences’ current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Readers are cautioned that actual results could differ materially from those expressed or implied in Alamar Biosciences’ forward-looking statements due to a variety of risks and uncertainties, which include, without limitation, risks and uncertainties related to intense competition in the proteomics market, exposure to legal proceedings, regulatory inquiries and other legal matters, failure to develop new assays or instruments, dependence on researchers who rely heavily on government funding, reductions in spending by research and academic institutions, the potential for products to be subject to more onerous regulation by the FDA or other regulatory requirements, the complexity of manufacturing Alamar Biosciences’ instruments and consumables, failure to obtain marketing authorizations for future products that are intended for clinical or diagnostic use, Alamar Biosciences’ ability to protect its intellectual property and other risks and uncertainties described in Alamar Biosciences’ filings with the Securities and Exchange Commission (SEC), including those described from time to time under the caption “Risk Factors” and elsewhere in Alamar Biosciences’ filings with the SEC, including its prospectus filed with the SEC pursuant to Rule 424(b)(4), dated April 16, 2026. Alamar Biosciences explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
Investor contact:
investors@alamarbio.com
Media contact:
media@alamarbio.com
Alamar Biosciences, Inc.
Condensed Consolidated Statements of Operations
(Unaudited, in thousands, except share and per share data)
|
|
Three Months Ended March 31, |
|
|||||
|
|
2026 |
|
|
2025 |
|
||
Revenue: |
|
|
|
|
|
|
||
Product revenue |
|
$ |
21,341 |
|
|
$ |
9,169 |
|
Service and other revenue |
|
|
4,694 |
|
|
|
3,922 |
|
Total revenue(1) |
|
|
26,035 |
|
|
|
13,091 |
|
Cost of revenue: |
|
|
|
|
|
|
||
Cost of product revenue(2) |
|
|
9,810 |
|
|
|
5,371 |
|
Cost of service and other revenue(2) |
|
|
1,768 |
|
|
|
1,331 |
|
Total cost of revenue |
|
|
11,578 |
|
|
|
6,702 |
|
Gross profit |
|
|
14,457 |
|
|
|
6,389 |
|
Operating expenses: |
|
|
|
|
|
|
||
Research and development(2) |
|
|
13,017 |
|
|
|
8,302 |
|
Selling, general and administrative(2) |
|
|
13,787 |
|
|
|
6,640 |
|
Total operating expenses |
|
|
26,804 |
|
|
|
14,942 |
|
Loss from operations |
|
|
(12,347 |
) |
|
|
(8,553 |
) |
Interest income, net |
|
|
539 |
|
|
|
786 |
|
Interest expense |
|
|
(223 |
) |
|
|
(46 |
) |
Loss on remeasurement of convertible notes |
|
|
(8,594 |
) |
|
|
— |
|
Other (expense) income, net |
|
|
(236 |
) |
|
|
154 |
|
Net loss before income tax |
|
|
(20,861 |
) |
|
|
(7,659 |
) |
Provision for income taxes |
|
|
464 |
|
|
|
— |
|
Net loss |
|
$ |
(21,325 |
) |
|
$ |
(7,659 |
) |
Net loss per share, basic and diluted |
|
$ |
(1.74 |
) |
|
$ |
(0.68 |
) |
Weighted-average common shares outstanding, basic and diluted |
|
|
12,259,811 |
|
|
|
11,258,870 |
|
|
|
Three Months Ended March 31, |
|
|||||
(in thousands) |
|
2026 |
|
|
2025 |
|
||
Instruments |
|
$ |
7,381 |
|
|
$ |
4,146 |
|
Consumables |
|
|
13,960 |
|
|
|
5,023 |
|
Services |
|
|
4,694 |
|
|
|
3,672 |
|
Other revenue |
|
|
— |
|
|
|
250 |
|
Total |
|
$ |
26,035 |
|
|
$ |
13,091 |
|
|
|
Three Months Ended March 31, |
|
|||||
(in thousands) |
|
2026 |
|
|
2025 |
|
||
Cost of product revenue |
|
$ |
14 |
|
|
$ |
8 |
|
Cost of service and other revenue |
|
|
22 |
|
|
|
13 |
|
Research and development |
|
|
392 |
|
|
|
229 |
|
Selling, general and administrative |
|
|
1,039 |
|
|
|
369 |
|
Total stock-based compensation expense |
|
$ |
1,467 |
|
|
$ |
619 |
|
Alamar Biosciences, Inc.
Condensed Consolidated Balance Sheets
(Unaudited, in thousands)
|
|
March 31, |
|
|
December 31, |
|
||||
ASSETS |
|
|
|
|
|
|
|
|
||
Current Assets |
|
|
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
|
64,586 |
|
|
$ |
|
30,002 |
|
Accounts receivable |
|
|
|
19,524 |
|
|
|
|
12,753 |
|
Inventory |
|
|
|
39,931 |
|
|
|
|
38,482 |
|
Prepaid expenses and other current assets |
|
|
|
17,432 |
|
|
|
|
13,468 |
|
Total current assets |
|
|
|
141,473 |
|
|
|
|
94,705 |
|
Restricted cash |
|
|
|
4,907 |
|
|
|
|
4,907 |
|
Property and equipment, net |
|
|
|
10,472 |
|
|
|
|
10,498 |
|
Operating lease right-of-use assets |
|
|
|
25,671 |
|
|
|
|
26,130 |
|
Capitalized software, net |
|
|
|
1,836 |
|
|
|
|
1,988 |
|
Other assets—noncurrent |
|
|
|
2,092 |
|
|
|
|
1,764 |
|
Total assets |
|
$ |
|
186,451 |
|
|
$ |
|
139,992 |
|
LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' DEFICIT |
|
|
|
|
|
|
|
|
||
Current Liabilities |
|
|
|
|
|
|
|
|
||
Accounts payable |
|
$ |
|
5,635 |
|
|
$ |
|
5,872 |
|
Accrued and other current liabilities |
|
|
|
16,814 |
|
|
|
|
15,759 |
|
Short-term operating lease liabilities |
|
|
|
1,599 |
|
|
|
|
2,099 |
|
Total current liabilities |
|
|
|
24,048 |
|
|
|
|
23,730 |
|
Long-term operating lease liabilities |
|
|
|
28,979 |
|
|
|
|
29,564 |
|
Warrant liabilities |
|
|
|
331 |
|
|
|
|
247 |
|
Term debt |
|
|
|
9,877 |
|
|
|
|
9,810 |
|
Convertible note |
|
|
|
65,094 |
|
|
|
|
— |
|
Other noncurrent liabilities |
|
|
|
1,197 |
|
|
|
|
599 |
|
Total liabilities |
|
|
|
129,526 |
|
|
|
|
63,950 |
|
Convertible preferred stock |
|
|
|
234,996 |
|
|
|
|
234,996 |
|
Stockholders’ deficit |
|
|
|
|
|
|
|
|
||
Founders preferred stock |
|
|
|
— |
|
|
|
|
— |
|
Common stock |
|
|
|
1 |
|
|
|
|
1 |
|
Additional paid-in capital |
|
|
|
12,108 |
|
|
|
|
9,892 |
|
Accumulated other comprehensive loss |
|
|
|
(80 |
) |
|
|
|
(72 |
) |
Accumulated deficit |
|
|
|
(190,100 |
) |
|
|
|
(168,775 |
) |
Total stockholders’ deficit |
|
|
|
(178,071 |
) |
|
|
|
(158,954 |
) |
Total liabilities, convertible preferred stock and stockholders' deficit |
|
$ |
|
186,451 |
|
|
$ |
|
139,992 |
|